早期穿刺移植物与隧道中心静脉导管在紧急血液透析通路中的随机对照试验与成本效果分析
该随机对照试验纳入121例需紧急血液透析通路的成人患者,比较早期穿刺移植物(ecAVG)与隧道中心静脉导管(TCVC)的菌血症发生率。6个月内TCVC组培养证实的菌血症发生率为16.4%,ecAVG组为3.3%,TCVC组死亡率也更高。两组治疗费用差异无统计学意义。
要点
- 紧急透析通路选用ecAVG较TCVC可降低6个月内培养证实的菌血症发生率。
- TCVC组死亡率高于ecAVG组,差异有统计学意义。
- 两种策略的治疗费用差异无统计学意义,ecAVG策略成本中性。
核心结论
- 与TCVC±AVF相比,ecAVG±AVF策略降低了需紧急血液透析通路患者的培养证实菌血症发生率和死亡率。
- ecAVG策略在费用方面呈成本中性。
研究设计与样本
- 随机对照试验,121例需紧急血液透析通路的成人患者按1:1随机分组。
- ecAVG±AVF组60例,TCVC±AVF组61例。
- 排除活动性全身性脓毒症、无解剖合适血管或预期寿命小于3个月的患者。
主要发现
- 6个月内培养证实的菌血症:TCVC组10例(16.4%),ecAVG组2例(3.3%),风险比0.2(95%CI 0.12-0.56,P=.02)。
- 死亡率:TCVC组16%(10例),ecAVG组5%(3例),风险比0.3(95%CI 0.08-0.45,P=.04)。
- 两组治疗费用差异无统计学意义(£11,393 vs £9,692,P=.24)。
关键数值与推荐
- 主要终点为6个月内培养证实的菌血症发生率,试验把握度设定为检测菌血症从24%降至5%(α=.05,β=.8)。
- 次要终点包括血栓形成、再干预和死亡率。
临床怎么用
- 对于需紧急血液透析通路的患者,可考虑优先选用ecAVG±AVF策略以降低菌血症和死亡风险。
- ecAVG策略不增加治疗费用,具有成本中性特点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Early cannulation arteriovenous grafts (ecAVGs) are proposed as an alternative to tunneled central venous catheters (TCVCs) in patients requiring immediate vascular access for hemodialysis (HD). We compared bacteremia rates in patients treated with ecAVG and TCVC. METHODS: The study randomized 121 adult patients requiring urgent vascular access for HD in a 1:1 fashion to receive an ecAVG with or without (+/-) an arteriovenous fistula (AVF; n = 60) or TCVC+/-AVF (n = 61). Patients were excluded if they had active systemic sepsis, no anatomically suitable vessels, or an anticipated life expectancy <3 months. The primary end point was the culture-proven bacteremia rate at 6 months, with the trial powered to detect a reduction in bacteremia from 24% to 5% (α = .05, β = .8). Secondary end points included thrombosis, reintervention, and mortality. A cost-effectiveness analysis was also performed. RESULTS: Culture-proven bacteremia developed in 10 patients (16.4%) in the TCVC arm ≤6 months compared with two (3.3%) in the ecAVG+/-AVF arm (risk ratio, 0.2; 95% confidence interval, 0.12-0.56; P = .02). Mortality was also higher in the TCVC+/-AVF cohort (16% [n = 10] vs 5% [n = 3]; risk ratio, 0.3; 95% CI, 0.08-0.45; P = .04). The difference in treatment cost between the two arms was not significant (£11,393 vs £9692; P = .24). CONCLUSIONS: Compared with TCVC+/-AVF, a strategy of ecAVG+/-AVF reduced the rate of culture-proven bacteremia and mortality in patients requiring urgent vascular access for HD. The strategy also proved to be cost-neutral.
引用
- Aitken E, Thomson P, Bainbridge L, et al. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. J Vasc Surg. 2017. PMID: 28236919. doi:10.1016/j.jvs.2016.10.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。